A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) in Subjects (2 Years and Older) With Molluscum Contagiosum
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2018
At a glance
- Drugs Cantharidin
- Indications Molluscum contagiosum
- Focus Therapeutic Use
- Sponsors Verrica Pharmaceuticals
- 07 Aug 2018 According to a Verrica Pharmaceuticals media release, complete clinical results from enrolled patients expected in the second half of 2018.
- 12 Jun 2018 Planned End Date changed from 9 May 2018 to 25 Jun 2018.
- 12 Jun 2018 Planned primary completion date changed from 25 Apr 2018 to 25 Jun 2018.